X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $8.81 million versus the consensus estimate of $2.28 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.